Persistent Growth-promoting effects of vosoritide in children with achondroplasia are accompanied by improvements in physical and social aspects of health related quality of life

Publication of impact on health-related quality of life from 3 year data with vosoritide. These data suggest that after 3 years of treatment, vosoritide demonstrates a…

Proposed Endocrine Funding Priorities for the NICHD Strategic Plan: Expert Opinion from the Pediatric Endocrine Society

Increasing Minority Participation in Clinical Research